1. Pink Sheet
  2. >>Geography
  3. >>Europe
  4. >>United Kingdom

‘Impossible' To Prepare UK Supply Chain For October No-Deal Brexit

 
• By Ian Schofield

The UK parliament's Exiting the EU Committee has heard strong words from industry representatives who say that the sector will not be ready for a no-deal Brexit in in October and that such a scenario would result in stockpiling problems, drug shortages and safety issues.  

Europe and United Kingdom political and economic relationship, 3d rendering background, Brexit concepts
An October No-Deal Brexit Would Cause Drug Supply Problems • Source: Shutterstock

Representatives of the pharmaceutical manufacturing and drug distribution industries in the UK have told a parliamentary committee that there is no way the sector will be ready for a “no-deal” Brexit at the end of October, partly because the timeframes are so compressed that there will be little time to prepare.

They also suggested that “talking up” a no-deal Brexit could “tip the scales” for companies thinking of investing in the UK, that there could be “critical” shortages of certain medicines, and that patient safety could be

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United Kingdom

Managed Access Agreement Fails To Help BioMarin’s Brineura Secure Routine Reimbursement In England

 
• By Francesca Bruce

BioMarin’s ultra-rare disease drug Brineura has breached cost-effectiveness thresholds for highly specialized treatments in England and looks set to be denied routine funding on the National Health Service.

Inclusive By Design: UK Pilots Diversity Plans For Drug & Device Trials

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

UK’s International Recognition Procedure: EU Dossier Faster Than US Or Canada

 
• By Eliza Slawther

Companies that use the European Medicines Agency as a reference regulator for the UK’s International Recognition Procedure can expect a faster approval than those that use other national regulators, such as those in the US and Canada, an MHRA spokesperson has said.

Industry On Making England’s HTA Innovation Lab A Success

 
• By Eliza Slawther

England’s health technology assessment institute, NICE, must ensure that there is clarity for manufacturers on how its methods and processes might change following testing in its sandbox environment, the Association of the British Pharmaceutical Industry said.

More from Europe